Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2024-12-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
第五届董事会第九次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's fifth board of directors' ninth (extraordinary) meeting. It details the meeting's attendance, the approval of several proposals including capital increase via debt-to-equity swap, employee stock plan lock-up expiration, borrowing from controlling shareholder, and extension of related party loans. The document includes voting results and references to related announcements published elsewhere. The content focuses on board decisions and governance matters rather than full financial statements or detailed financial performance. The document length is about 2049 characters, which is relatively short and typical for a board meeting resolution announcement. Therefore, this document fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2024-12-25 Chinese
关于以债转股方式对全资子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a listed company (绿康生化股份有限公司) regarding a capital increase in its wholly-owned subsidiary through debt-to-equity conversion. It includes details about the subsidiary, the capital increase method, financial data, board resolutions, and risk disclosures. The document is relatively short (1834 characters) and focuses on a financing activity involving capital structure changes. It is not a full financial report, audit report, or earnings release. It is not a notice of dividend, voting results, or management change. The content fits the definition of a Capital/Financing Update (CAP), as it updates on company financing activities and capital structure changes.
2024-12-25 Chinese
关于向控股股东借款暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related party transaction where the company borrows funds from its controlling shareholder. It details the terms of the loan, the relationship between the parties, approval by the board and independent directors, and confirms compliance with relevant regulations. There are no financial statements or comprehensive financial data presented, nor is this a report or earnings release. The document is a formal disclosure of a capital/financing update related to borrowing and associated terms. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so it is not RPA or RNS.
2024-12-25 Chinese
第五届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company 绿康生化股份有限公司 regarding decisions made at their eighth meeting of the fifth session. It includes voting results on matters such as capital increase by debt-to-equity swap, loans from controlling shareholders, and loan extension related to connected transactions. The document is a formal announcement of meeting resolutions and voting outcomes, not a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a notice of a report publication. It fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement of board meeting resolutions and related disclosures.
2024-12-25 Chinese
关于关联借款展期暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of a related party loan between the company and its controlling shareholder. It details the terms of the loan extension, the approval process by the board and independent directors, and compliance with relevant stock exchange rules. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document is a formal disclosure of a related party transaction, specifically a financing update about borrowing terms and conditions. This fits the category of Capital/Financing Update (CAP). The document length is short and focused on a specific financing event, not a full report or regulatory filing. Therefore, the classification is CAP with high confidence.
2024-12-25 Chinese
关于召开2024年第四次临时股东会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2024 fourth extraordinary general meeting of shareholders for the company 绿康生化股份有限公司. It includes information about the meeting date, agenda items, voting procedures (both in-person and online), registration details, and proxy forms. The content focuses on informing shareholders about the meeting logistics and agenda proposals to be voted on, rather than presenting financial results or reports. The document length is 4771 characters, which is relatively short and consistent with an announcement rather than a full report. There is no financial data or management discussion present. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which is used to provide shareholders with information and request votes for meetings.
2024-12-20 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.